Market Research Future published a cooked research report on Global Cancer Biomarker Market. By Major Industry Trends, Business Analysis, Major Segments and Sub segments. Cancer Biomarker Market Report Gains Momentum with a Striking CAGR of 15.8% by 2023.
Avail Premium Sample Copy at https://www.marketresearchfuture.com/sample_request/5378
Cancer Biomarker Market – Scenario
Cancer biomarkers are molecules released due to tumor which are indicative of the presence of cancer in the body and are used for the diagnosis and prognosis, of the disease and its stages.
Dynamics of Cancer Biomarker Market – Drivers
Early detection remains the elusive holy grail of cancer diagnosis due to its imminent importance in determining the mortality rate and quality of life of the patient. Thus early detection is the critical driver of the market, which can reduce the end cost of the treatment due to lower frequency of treatment needed.
The growing prevalence and incidence of cancer is the second most important driver of the market, as it drives the demand directly. The world health organization estimates that cancer was responsible for 8.8 million deaths in 2015 with a mortality rate of nearly 1 in 6 patients. The lung cancer immunotherapy is anticipated to witness fastest growth during the forecast period. In 2015 alone, lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer claimed 1.69 million, 788,000, 774 thousands, 754 thousands, and 571 thousands lives respectively. Cancer is expected to witness an alarming growth, with world health organization estimating about 14 million new cancer cases each year which is expected to increase further by 70% over the next two decades.
Technological drivers include growing sensitivity and selectivity of detection technology, development of liquid biopsy and others. The cross applications potential of the technology has resulted in spurts of investments which is expected to trigger a surge of innovative start-ups. The tax and other incentives provided by governments are added attractions for the market.
Global Cancer Biomarker Market – Prominent Players
- Bristol-Myers Squibb
- GlaxoSmithKline
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Becton Dickinson
- PerkinElmer
- And more.
Avail Stunning Discount @ https://www.marketresearchfuture.com/check-discount/5378
Restraints:
Prohibitive costs of cancer biomarker technology coupled with scarcity of trained manpower due to the nascent stage of the technology are prime restraints on the market. However the faster results obtained by the technology coupled with the ability to detect the prognosis of the disease lowers the end cost. The added benefit of leveraging the diagnosis molecular data for selecting the course of the treatment on the basis of the molecular characteristics of the cancer will negate the cost disadvantage of the technology. The high cost of development is another constraint on the market. However the cross functional nature of the technology with applications in drug development, diagnosis of other diseases such as cardiovascular diseases, liver diseases is expected to drive a momentous returns on investments providing justification for the high development risks.
Segmentation of Cancer Biomarker Market:
The report is segmented on the basis of types, applications and end users to get a comprehensive grasp of the market in terms of growth potential.
Types – protein biomarker, genetic biomarker and others.
Application – diagnostic (imaging and non- Imaging), prognostic and therapeutic. The diagnostic sub-segment is further classified into.
End users – pharmaceutical and biotechnology companies, diagnostic tool companies, healthcare it/big data companies, clinical laboratories
Regional Analysis of Cancer Biomarker Market:
The report is segmented into America, Europe, Asia Pacific, and the Middle East & Africa to have a bird’s view of the differential potential and equity of the market.
North America led by U.S. is expected to possess the greatest share of the market in 2016, closely followed by Europe. However the historical faster adoption rates for novel technologies in the U.S. is expected to increase the market discrepancy between the two regions in the favor of the U.S. Europe is expected to be led by Germany, France and the Scandinavian regions of Finland, Norway and Iceland.
Asia Pacific market is expected to be the fastest growing region owing to the explosive growth of cancer cases and the lower costs of treatment. China, India, and South Korea are expected to witness significant expansion of the cancer biomarkers market. Rise in medical tourism is another competitive advantage afforded by the Asia Pacific region.
Major TOC:
1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Impact Analysis
6 Asia Pacific Aesthetics Market, By Procedure
7 Asia Pacific Aesthetics Market, By Product
8 Asia Pacific Aesthetics Market, By Application
9 Asia Pacific Aesthetics Market, By End User
10 Asia Pacific Aesthetics Market, By Country/Region
11 Competitive Landscape
12 Company Profiles
13 Conclusion
14 Appendix
Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/5378
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
